Scullard G H, Pollard R B, Smith J L, Sacks S L, Gregory P B, Robinson W S, Merigan T C
J Infect Dis. 1981 Jun;143(6):772-83. doi: 10.1093/infdis/143.6.772.
Twenty patients with chronic active hepatitis and 12 patients with chronic persistent hepatitis associated with hepatitis B virus (HBV) infection were treated with human leukocyte interferon or adenine arabinoside alone or in combination. With interferon alone, four of 16 patients showed a permanent disappearance of HBV-associated DNA polymerase (DNAP) activity from serum. Of six patients treated with adenine arabinoside alone, only one patient became permanently DNAP-negative. With a regimen of multiple cycles of combined interferon and adenine arabinoside, seven of 16 male patients became permanently DNAP-negative. Of 69 patients who met the criteria for admission to the program, spontaneous decreases in DNAP activity without treatment were observed in only 9% during a mean observation period of 10 months. In general, patients with chronic active hepatitis, those who are female, and those with a history of recent steroid therapy responded to the antiviral agents significantly better than did the other patients.
20例慢性活动性肝炎患者和12例与乙型肝炎病毒（HBV）感染相关的慢性持续性肝炎患者接受了单独或联合使用人白细胞干扰素或阿糖腺苷的治疗。单独使用干扰素时，16例患者中有4例血清中与HBV相关的DNA聚合酶（DNAP）活性永久消失。在单独接受阿糖腺苷治疗的6例患者中，只有1例患者的DNAP转为永久阴性。采用干扰素和阿糖腺苷联合的多周期治疗方案时，16例男性患者中有7例的DNAP转为永久阴性。在符合该项目入组标准的69例患者中，在平均10个月的观察期内，未经治疗而DNAP活性自发下降的情况仅在9%的患者中出现。总体而言，慢性活动性肝炎患者、女性患者以及近期有类固醇治疗史的患者对抗病毒药物的反应明显优于其他患者。
